Cereno Scientific is preparing to submit an application to start Phase II study
Cereno Scientific is preparing to within shortly submit a clinical trial application regarding the company’s Phase II study with its drug candidate CS1. This means that the application will be submitted earlier than in the third quarter of 2019, which was previously communicated. The company’s intention is to initiate the study during the first half of 2020, provided the approval of the relevant authorities and the ethics committee and that sufficient study material has been produced.“Cereno Scientific, together with its partner Galenica and the CRO company OCT Group has been working hard